Report
Phase 1 trial finds personalized vaccines plus PD-1 blockade feasible for patients with high-grade serous ovarian cancer
Nature Medicine says the treatment led to tumor-specific immune responses in many patients with high-grade serous ovarian cancer.
TLDR
Nature Medicine says a phase 1 trial found that personalized neoantigen vaccines combined with PD-1 blockade were feasible for treating patients with high-grade serous ovarian cancer. The treatment led to tumor-specific immune responses in many patients.
Combined views
977
1 Source, first seen ago
